Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.verified

ALPN

Price:

$64.97

Market Cap:

$4.46B

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with Ab...[Read more]

Industry

Biotechnology

IPO Date

2015-06-17

Stock Exchange

NASDAQ

Ticker

ALPN

The Enterprise Value as of November 2024 (TTM) for Alpine Immune Sciences, Inc. (ALPN) is 4.43B

According to Alpine Immune Sciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.43B. This represents a change of 277.85% compared to the average of 1.17B of the last 4 quarters.

Alpine Immune Sciences, Inc. (ALPN) Historical Enterprise Value (quarterly & annually)

How has ALPN Enterprise Value performed in the past?

The mean historical Enterprise Value of Alpine Immune Sciences, Inc. over the last ten years is 207.15M. The current 4.43B Enterprise Value has changed 213.92% with respect to the historical average. Over the past ten years (40 quarters), ALPN's Enterprise Value was at its highest in in the March 2024 quarter at 2.55B. The Enterprise Value was at its lowest in in the June 2015 quarter at -37512150.00.

Quarterly (TTM)
Annual

Average

207.15M

Median

89.53M

Minimum

10.61M

Maximum

919.00M

Alpine Immune Sciences, Inc. (ALPN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Alpine Immune Sciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 556.13%

Maximum Annual Enterprise Value = 919.00M

Minimum Annual Increase = -77.68%

Minimum Annual Enterprise Value = 10.61M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023919.00M272.68%
2022246.59M-19.04%
2021304.58M21.80%
2020250.05M253.53%
201970.73M59.10%
201844.46M-36.15%
201769.63M556.13%
201610.61M-77.68%
201547.54M-56.11%
2014108.32M-27.97%

Alpine Immune Sciences, Inc. (ALPN) Average Enterprise Value

How has ALPN Enterprise Value performed in the past?

The current Enterprise Value of Alpine Immune Sciences, Inc. (ALPN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

490.06M

5-year avg

358.19M

10-year avg

207.15M

Alpine Immune Sciences, Inc. (ALPN) Enterprise Value vs. Peers

How is ALPN’s Enterprise Value compared to its peers?

Alpine Immune Sciences, Inc.’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (0), greater than Day One Biopharmaceuticals, Inc. (222.97M), greater than Acumen Pharmaceuticals, Inc. (963.46M), greater than Amylyx Pharmaceuticals, Inc. (139.19M), greater than MoonLake Immunotherapeutics (291.98M), greater than Anebulo Pharmaceuticals, Inc. (3.05B), greater than Adagene Inc. (36.46M), greater than Acrivon Therapeutics, Inc. Common Stock (22.22M), greater than AnaptysBio, Inc. (163.47M), greater than Mineralys Therapeutics, Inc. (502.56M), greater than Tenaya Therapeutics, Inc. (523.81M), greater than Bicycle Therapeutics plc (194.85M), greater than IGM Biosciences, Inc. (537.81M), greater than Monte Rosa Therapeutics, Inc. (531.62M), greater than Stoke Therapeutics, Inc. (439.72M), greater than null (457.69M),

Build a custom stock screener for Alpine Immune Sciences, Inc. (ALPN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alpine Immune Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alpine Immune Sciences, Inc. (ALPN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alpine Immune Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Alpine Immune Sciences, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Alpine Immune Sciences, Inc. (ALPN)?

What is the 3-year average Enterprise Value for Alpine Immune Sciences, Inc. (ALPN)?

What is the 5-year average Enterprise Value for Alpine Immune Sciences, Inc. (ALPN)?

How does the current Enterprise Value for Alpine Immune Sciences, Inc. (ALPN) compare to its historical average?